The role of modern methods of nuclear medicine in the diagnosis of radiation disease in patients after radiation and radionuclide therapy-Reference-Cited by-同舟云学术

The role of modern methods of nuclear medicine in the diagnosis of radiation disease in patients after radiation and radionuclide therapy

Published:2022 Issue: Volume: Page:18-34
ISSN:2707-0700
Container-title:Radiation Diagnostics, Radiation Therapy
language:
Short-container-title:RDRT

Author:

Korol P.¹,Shcherbina O.²,Kostylev M.³,Severin Yu.²,Ivchuk V/²

Affiliation:

1. PL Shupyk National University of Health of Ukraine, Kyiv, Ukraine OO Shalimov National Institute of Surgery and Transplantology, Kyiv, Ukraine

2. P.L. Shupyk National University of Health of Ukraine, Kyiv, Ukraine

3. OO Shalimov National Institute of Surgery and Transplantology, Kyiv, Ukraine

Abstract

The review considers the effectiveness of modern methods of nuclear medicine in the diagnosis of radiation disease to normal tissues in patients after radiation and radionuclide therapy. At the present stage, the assessment of radiation disease in the use of radiation and radionuclide therapy using nuclear medicine is one of the priority tasks in oncology. Hybrid methods of nuclear medicine have the ability to objectively identify and evaluate high-resolution radiation disease to normal tissues in order to predict and monitor the effects of radiation and radionuclide therapy on them. Key words: radiation disease, nuclear medicine, radiation therapy, radionuclide therapy.

Publisher

Institute of Nuclear Medicine and Diagnostic Radiology of the National Academy of Medical Sciences of Ukraine

Subject

General Earth and Planetary Sciences,General Environmental Science

Reference123 articles.

1. Ahlstedt J, Johansson E, Sydoff M. Non-invasive imaging methodologies for assessment of radiation damage to bone marrow and kidneys from peptide receptor radionuclide therapy. Neuroendocrinology. 2020;110:130–8. https://doi.org/10.1159/000500473.

2. Ahmadzadehfar H, Zimbelmann S, Yordanova A. Radioligand therapy of metastatic prostate cancer using 177Lu- PSMA-617 after radiation exposure to 223Ra-dichloride. Oncotarget. 2017;8:55567–74. https://doi.org/10.18632/oncotarget.15698.

3. Agool A, Slart RHJA, Thorp KK. Effect of radiotherapy and chemotherapy on bone marrow activity: a 18F-FLT-PET study. Nucl Med Commun. 2011;32:17–22. https://doi.org/10.1200/jco.2012.44.1659.

4. Alsultan AA, Smits MLJ, Barentsz MW. The value of yttrium - 90 PET/CT after hepatic radioembolization : a pictorial essay. Clin Transl Imaging. 2019;7:303–12. https://doi.org/10.1007/s40336-019-00335-2.

5. Andrews DW, Scott CB, Sperduto PW. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 2004;363:1665–72. http://www.ncbi.nlm.nih.gov/pubmed/15158627.